Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Centivax, Inc. | South San Francisco, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Invvax, Inc. | Cypress, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Crestone, Inc. | Boulder, CO | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Zabbio, Inc. | Del Mar, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Panorama Research Incorporated | Sunnyvale, CA | — |
About the company
Trellis Bioscience, Inc. is a corporate for-profit organization located in Redwood City, California, registered in SAM.gov since 2010 and specializing in developing therapeutic antibodies for infectious disease treatments. The company focuses on innovative medical research, particularly targeting bacterial infections and biofilm disruption through advanced monoclonal antibody technologies. Trellis Bioscience is actively engaged in developing therapeutic interventions for challenging medical conditions, with a primary emphasis on creating antibody-based treatments that can enhance antibiotic effectiveness and combat bacterial resistance.
The available federal contract records indicate that Trellis Bioscience has participated in sub-contract work, specifically a notable collaboration with Trustees of Boston University for a first-in-human Phase 1 trial of TRL1068. This sub-contract award involved developing a monoclonal antibody treatment targeting bacterial biofilms, with a focus on disrupting the physiological mechanisms that contribute to antibiotic resistance. The contract work demonstrates the company's expertise in translational research, leveraging mouse model studies to advance clinical trial preparations and develop innovative therapeutic approaches for infectious disease treatments.
Trellis Bioscience has secured multiple federal grant awards from the National Institute of Allergy and Infectious Diseases, focusing on advanced therapeutic antibody research. These grants include a significant $297,917 cooperative agreement for a Phase 1 safety trial of TRL1068, an inhaled therapeutic targeting bacterial pneumonia, and earlier grants exploring biofilm-disrupting antibodies for respiratory and musculoskeletal infections. The grant awards support the company's research into developing novel antibody treatments, with a specific emphasis on creating therapies that can effectively address challenging bacterial infections. The grants have enabled Trellis Bioscience to conduct critical research, including safety trials for inhaled therapeutics, developing treatments for prosthetic joint infections, and exploring innovative approaches to combating bacterial biofilms across different infection types.
Quick answers
Is Trellis Bioscience, Inc. registered in SAM.gov?
Trellis Bioscience, Inc.'s SAM.gov registration expired on October 7, 2026.
What is Trellis Bioscience, Inc.'s CAGE code?
Trellis Bioscience, Inc.'s CAGE code is 619E4, and its Unique Entity ID (UEI) is LFEJER34NQU6.
What is Trellis Bioscience, Inc.'s most recent federal award?
Trellis Bioscience, Inc.'s most recent federal grant award is Human antibody for acute infection treatment of RSV (SB1AI191674), from National Institute of Allergy and Infectious Diseases (NIH), on August 1, 2026.
On GovTribe
See Trellis Bioscience, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors